Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Colorectal Neoplasms × trilaciclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Neoplasm Metastasis 1 Limited Stage Small Cell Lung Cancer 1 Colorectal Neoplasms 1 Breast Neoplasms 1

Interventions

Fluorouracil 131 Leucovorin 127 Oxaliplatin 93 Bevacizumab 85 Irinotecan 74 Capecitabine 63 Cetuximab 46 Folfox protocol 32 Panitumumab 18 regorafenib 16 trifluridine tipiracil drug combination 15 Drug Therapy 14 Chemotherapy, Adjuvant 13 IFL protocol 10 Floxuridine 10 Radiotherapy 9 Tegafur 7 Neoadjuvant Therapy 7 Levoleucovorin 7 Laparoscopy 7 Aspirin 7 pembrolizumab 6 Celecoxib 6 atezolizumab 5 XELOX 5 Trifluridine 5 Mitomycin 5 Colonoscopy 5 sintilimab 4 dehydroftorafur 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04607668 2024-11-26

PRESERVE1

G1 Therapeutics, Inc.

Phase 3 Terminated

326 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡